ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Similar documents
The acquisition of Fortitech

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ADM to Acquire WILD Flavors

January 30, 2018 Dow Wilson President and Chief Executive Officer

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

BALCHEM CORPORATION. Q Investor Relations Presentation

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Investor Presentation

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

Continued value growth

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Forward Looking Information

Harm de Wildt MD TNI

Myriad Genetics Corporate Presentation 06/13/2018

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

DSM Capital Markets Day 2018

DuPont Nutrition & Health Craig Binetti, President

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value growth in Human Nutrition & Health

FORM8-K HILLENBRAND,INC.

JP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011

Corporate Presentation

Südzucker Group Capital market forum Rhine Neckar

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Investor Presentation

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Driving Profitable Growth

Nomura Healthcare Conference

Balchem Corporation Investor Relations

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Cochlear Limited 2017 Annual General Meeting Chairman s Address

Welcome to the Full -Year Results Press Conference

A world leader in allergy immunotherapy

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

GROWTH NOW! Franck Riboud

Nestlé Investor Seminar 2008

FIRSTQUARTER2018 RESULTSPRESENTATION

Coloplast A/S. Investor presentation 1H 2005/06

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Ipsen Acquisition of Clementia Pharmaceuticals. February 25, 2019

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

2015 Investor Conference

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT

Food & Beverages Food for a growing world

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

For personal use only

INVESTOR PRESENTATION

Financial Presentation

DS-8201 Strategic Collaboration

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Third-quarter results 2013

Global EHS Leaders Survey 2017: EHS Consulting Brands

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

DELICA D:5 ACTIVE GEAR 0

Reynolds American to Acquire Lorillard

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Investor Presentation. Q April 26, 2018

For personal use only

Endesa 1Q 2017 Results 09/05/2017

For personal use only

Genomic Health. Kim Popovits, Chairman, CEO and President

Consolidated: Financial Summary

Forward-Looking Statements

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

Investor Presentation. Q October 26, 2017

Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595

Efforts start to pay off in the fourth quarter

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

Enel Américas 1Q 2018 results

Agenda. Company Overview. Industry Overview. Outlook Q&A. Mammography Osteoporosis & Other Merger with Cytyc

Putting ALK on the right growth trajectory

Results Briefing. 15 ~ 17 May 2007

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Health for Humanity 2020 Goals 2

www. isotopeworld.com Advanced Medical Isotope Corporation

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

N a s d a q : I N S Y

HILLENBRAND INDUSTRIES INC

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Transcription:

ADM to Acquire Neovia and Probiotics International Limited July 2, 2018

Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates of future economic circumstances, industry conditions, Company performance and financial results. These statements are based on many assumptions and factors that are subject to risk and uncertainties. ADM has provided additional information in its reports on file with the SEC concerning assumptions and factors that could cause actual results to differ materially from those in this presentation, and you should carefully review the assumptions and factors in our SEC reports. To the extent permitted under applicable law, ADM assumes no obligation to update any forward-looking statements as a result of new information or future events.

ADM Value Creation Strategy 3

Five Growth Platforms at ADM 4 Taste Human Nutrition Animal Nutrition Health & Wellness Carbohydrates Focus of Today s Discussion

Building the Nutrition Business Leader 5 Human Nutrition (WFSI) Enablers/Platforms Bolt-ons Organic Growth Projects WILD Flavors (natural systems) Amazon Flavors SCI Eatem Foods Caterina Foods Harvest Innovations Tianjin Fibersol Berlin Colors Campo Grande Specialty Proteins Innovation Centers Pea Protein Animal Nutrition (global capabilities) Crosswind Industries (pet treats) China Premix China Aquaculture Effingham/Columbus Premix Health & Wellness Biopolis (world-class bioactives R&D) Mayo Clinic Collaboration Vland Biotech Collaboration Davis, CA Biotech Lab

Overview of Neovia and Protexin 6 Neovia: A Transformative Step for ADM Animal Nutrition Largest ADM acquisition since WILD Would create a global leader in specialty animal nutrition, with estimated 2018 revenue of $3.5 billion Would significantly scale ADM s Nutrition division as part of ADM s stated strategy to expand the company s capabilities in specialty and value-added products Protexin: Important Expansion of Health & Wellness Platform Strong commercial presence complements ADM s existing research and development capabilities Creates fully integrated probiotics and nutraceuticals business

Neovia: A Leading Global Provider of Value-added Animal Nutrition Products and Solutions 7 FY 2018E EBITDA Breakdown Aquaculture 11% Additives & Ingredients 14% Asia 10% Petcare 22% Central America 26% By Business Line By Geography Global Additives 15% Premix & Services and Complete Feed 53% Western Europe 20% EEMEA 6% South America 23% Robust business model based on a multi-activity, multi-species and multiregion approach supplying innovative solutions for animal nutrition Leading positions and strong brand portfolio focused on expansion in attractive and high growth value-added segments (e.g., additives and ingredients, pet care and aquaculture) Geographically diversified revenue and EBITDA base, with strong positions in Western Europe as well as in key growth markets (e.g., Brazil, Mexico, Southeast Asia, Africa) Strong innovation, along with R&D capabilities coupled with deep technical and industry expertise Global innovation center in St. Nolff, France 11 global research centers with 140 dedicated scientists 40+ partnerships with universities in 17 countries Headquartered in France, with ~8,200 employees, 72 production sites and presence in 25 countries (serving 90+ countries with export activity) Strong management team with extensive global industry expertise

ADM + Neovia Creates a Global Leader in Animal Nutrition and a Strong Platform for Continued Growth 8 Product Lines Premix Complete Feed Species Poultry Swine Combined Capabilities and Expertise Differentiated portfolio of attractive and fast-growing product lines across a broad range of species Fills major gaps in ADM s current animal nutrition portfolio Ingredients Pet Care Aquaculture Additives Amino Acids Cattle Dog Fish Horse Cat Shrimp Presence Sales Neovia R&D Global Presence and Reach $3.5B Estimated CY 2018 Total Sales Strong Innovation Capabilities Complementary geographic presence creates global footprint and distribution network across key mature and growth markets Global innovation and R&D capabilities Ability to cross-leverage expertise in animal and human nutrition Enhanced ability to offer value-added solutions to a global customer base

Neovia: Significant Synergy Opportunities 9 50M Significant EBITDA Synergies Annual Run-rate Synergies By Fourth Full Year Following Closing Innovation and R&D synergies with our other Nutrition businesses Opportunities to combine existing and new products and expertise to create both human and animal systems and solutions Cross-selling and expansion opportunities across products and geographies Streamlining of direct and indirect purchasing spend and other expenses via integration into ADM s broader Nutrition operations Optimization of global footprint Implementation of ADM Operational Excellence standards Leveraging of ADM s global scale, transportation and logistics infrastructure, and processing footprint Other Value Levers Additional revenue synergies via development of value-added systems and integrated solutions leveraging the broader ADM Nutrition platform Ability to deliver premier products to animal and human nutrition Platform synergies, including enhanced ability to drive further value creation through future bolt-on M&A Combined Capabilities, Expertise and Experience to Drive Shareholder Value

Building a World Class, Fully Integrated Probiotics and Nutraceutical Platform 10 Probiotics International Limited (PIL), based in the U.K., is a leader in both human healthcare and animal probiotics, with a focus on the human health, veterinary (including companion animal), equine, and agriculture markets With its leading Protexin brand and other sub-brands, the acquisition will enable ADM to expand into business-toconsumer supplements in the human nutrition space Value creation through a combination of cost and revenue synergies: Complements ADM s recent expansion of its H&W business Strong commercial capabilities in sales and distribution, consumer marketing, regulatory affairs and dietary supplements applications development will also complement Biopolis R&D capabilities

Neovia Transaction Overview 11 Transaction Value ADM to acquire 100% of Neovia, a leading global provider of value-added animal nutrition products and solutions Transaction value of 1.535 billion, including assumption of ~ 200 million of Neovia net debt Reflects a multiple of 14.1x FY 2018E EBITDA 1, and 9.7x adjusted for full run-rate EBITDA synergies Value Creation Expect to realize run-rate EBITDA synergies of ~ 50 million by the fourth full year following transaction close Additional value upside and growth potential driven by development of integrated solutions leveraging combined animal and human nutrition capabilities and expertise Platform acquisition upon which to drive further value through future bolt-on M&A Expect transaction to be EPS accretive in the first full year after close, with a ROIC above ADM s long-term cost of capital by the end of the year three Financing and Capital Allocation Closing Purchase price to be paid 100% in cash Commitment to a capital structure and financial policy commensurate with a strong Investment Grade rating No impact to ADM s dividend or share repurchase strategies Retention of significant financial flexibility Subject to regulatory approvals and other customary closing conditions Targeted to close in Q4 2018 1 Neovia fiscal year ending June 30 th

Protexin Transaction Overview 12 Transaction Value and Consideration ADM to acquire 100% of Probiotics International Limited (PIL), a leading global provider of value-added nutritional products and solutions Transaction value of 185 million Reflects a multiple of 16.2x FY 2018E EBITDA 1, and 10.6x adjusted for full run-rate EBITDA synergies Purchase price to be paid 100% in cash Value Creation Expect to realize synergies driven by revenue synergies and efficiencies in the product development process Synergies include significant benefits from leveraging PIL s sales and distribution network and brands for current and future Biopolis and other ADM Health & Wellness products Expect transaction to be EPS accretive in the first full year after close, with ROIC above ADM s long-term cost of capital by the end of year three Closing Subject to regulatory approvals and other customary closing conditions Targeted to close in Q3 2018 1 PIL fiscal year ending July 31 st

Building a Leading Nutrition Platform 13 Nutrition comprises a significant and expanding portion of ADM s total operating profit ADM FY 2014 Adjusted Operating Profit (as Recast) Pro Forma 1 ADM FY 2017 Adjusted Operating Profit (as Recast) Nutrition 7% Oilseeds 36% Nutrition 15% Oilseeds 30% Other 2% Other 2% Origination 19% Origination 15% Carbohydrate Solutions 36% Carbohydrate Solutions 38% Nutrition: $258 million Nutrition: $422 million 1 Pro forma figure includes FY 2018E EBIT for Neovia and PIL. Excludes transaction synergies.

Q&A